# Edaravone Dexborneol for Treatment of Acute Ischemic Stroke With Endovascular Therapy in Extended Time Windows

Study · id `cardio:ct-nct04817527` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT04817527](<https://clinicaltrials.gov/study/NCT04817527>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT04817527

Browse, organ or system: Brain  
Browse, condition area: Stroke  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 200 participants.

## Technical summary

Registry record NCT04817527. Randomized; single masking; primary purpose treatment. Start 2021-10-01 (actual); primary completion 2022-12-01 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; single masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 200 participants (planned count; ClinicalTrials.gov record NCT04817527, source copy `cardio:ctgov-nct04817527-2022-04-01`, retrieved 2026-10-26)
- Started: 2021-10-01 (actual) (ClinicalTrials.gov record NCT04817527, source copy `cardio:ctgov-nct04817527-2022-04-01`, retrieved 2026-10-26)
- Primary completion: 2022-12-01 (anticipated) (ClinicalTrials.gov record NCT04817527, source copy `cardio:ctgov-nct04817527-2022-04-01`, retrieved 2026-10-26)
- Completion: 2022-12-31 (anticipated) (ClinicalTrials.gov record NCT04817527, source copy `cardio:ctgov-nct04817527-2022-04-01`, retrieved 2026-10-26)
- Countries: China (ClinicalTrials.gov record NCT04817527, source copy `cardio:ctgov-nct04817527-2022-04-01`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct04817527-2022-04-01`, retrieved 2026-10-26)

## The registry's words

- Brief title: Edaravone Dexborneol for Treatment of Acute Ischemic Stroke With Endovascular Therapy in Extended Time Windows
- Acronym: EXISTENT
- Condition: Stroke, Ischemic
- Intervention (Drug): Edaravone Dexborneol
- Lead sponsor: First Affiliated Hospital Xi'an Jiaotong University
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Ischemic stroke (`cardio:ischemic-stroke`)
- Registry condition terms include this condition: Stroke (`core:stroke`)
- Registry lists this organization as the lead sponsor: First Affiliated Hospital Xi'an Jiaotong University (`cardio:org-first-affiliated-hospital-xi-an-jiaotong-university`)

## Provenance

Content hash: 805b84e1b631570cbdb276224c80a938b169c5f3f55789a07fd9e6bdcb92dc46
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
